



Associations between physical activity and cognitive dysfunction in older companion dogs: results from the Dog Aging Project

Emily E. Bray · David A. Raichlen · Kiersten K. Forsyth · Daniel E. L. Promislow · Gene E. Alexander · Evan L. MacLean · Dog Aging Project Consortium

Received: 20 April 2022 / Accepted: 2 September 2022 / Published online: 21 September 2022
© The Author(s), under exclusive licence to American Aging Association 2022

Abstract Canine cognitive dysfunction (CCD) is a form of dementia that shares many similarities with Alzheimer’s disease. Given that physical activity is believed to reduce risk of Alzheimer’s disease in humans, we explored the association between physical activity and cognitive health in a cohort of companion dogs, aged 6–18 years. We hypothesized that higher levels of physical activity would be associated with lower (i.e., better) scores on a cognitive dysfunction rating instrument and lower prevalence of

dementia, and that this association would be robust when controlling for age, comorbidities, and other potential confounders. Our sample included 11,574 companion dogs enrolled through the Dog Aging Project, of whom 287 had scores over the clinical threshold for CCD. In this observational, cross-sectional study, we used owner-reported questionnaire data to quantify dog cognitive health (via a validated scale), physical activity levels, health conditions, training history, and dietary supplements. We fit regression models with measures of cognitive health as the outcome, and physical activity—with several important covariates—as predictors. We found a significant negative relationship between physical activity and current severity of cognitive dysfunction symptoms (estimate = -0.10 , 95% CI: -0.11 to -0.08 , $p < 0.001$),

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11357-022-00655-8>.

Gene E. Alexander and Evan L. MacLean contributed as senior authors

E. E. Bray (✉) · E. L. MacLean
Arizona Canine Cognition Center, School
of Anthropology, University of Arizona, Tucson, AZ, USA
e-mail: ebray@arizona.edu

E. E. Bray
Canine Companions for Independence, National
Headquarters, Santa Rosa, CA, USA

D. A. Raichlen
Human and Evolutionary Biology Section, Department
of Biological Sciences, University of Southern California,
Los Angeles, CA, USA

K. K. Forsyth
College of Veterinary Medicine & Biomedical Sciences,
M University, Texas A &, College Station, TX, USA

D. E. L. Promislow
Department of Laboratory Medicine and Pathology,
University of Washington School of Medicine, Seattle,
WA, USA

D. E. L. Promislow
Department of Biology, University of Washington, Seattle,
WA, USA

G. E. Alexander · E. L. MacLean
Department of Psychology, University of Arizona, Tucson,
AZ, USA

G. E. Alexander
Evelyn F. McKnight Brain Institute, University of Arizona,
Tucson, AZ, USA

extent of symptom worsening over a 6-month interval (estimate = -0.07 , 95% CI: -0.09 to -0.05 , $p < 0.001$), and whether a dog reached a clinical level of CCD (odds ratio = 0.53 , 95% CI: 0.45 to 0.63 , $p < 0.001$). Physical activity was robustly associated with better cognitive outcomes in dogs. Our findings illustrate the value of companion dogs as a model for investigating relationships between physical activity and cognitive aging, including aspects of dementia that may have translational potential for Alzheimer's disease. While the current study represents an important first step in identifying a relationship between physical activity and cognitive function, it cannot determine causality. Future studies are needed to rule out reverse causation by following the same dogs prospectively over time, and to evaluate causality by administering physical activity interventions.

Keywords Canine · Canine cognitive dysfunction · Healthy aging · Physical activity

Introduction

Alzheimer's disease is a devastating, age-related progressive neurodegenerative brain disorder that leads to cognitive decline and dementia. It is therefore a high priority for researchers to identify early, modifiable risk factors that can be targeted as interventions [1, 2]. Over the past few decades, physical

activity has emerged as one such factor that may play an important role in reducing the risk of Alzheimer's disease. There is evidence in humans that engaging in physical activity can have protective effects on cognitive function [3, 4]. In one large interventional study of adults with memory impairment, participating in a physical activity program for 6 months led to measurable increases in cognitive performance over the next year and a half [5]. In a different intervention, researchers documented an increase in hippocampal volume linked to aerobic exercise training [6]. A meta-analysis across 12 cohorts including thousands of participants also concluded that physical activity significantly protected against cognitive decline, even at low to moderate levels [7]. A recent study found that late-life physical activity was associated with higher presynaptic protein levels, known to positively affect cognition [8]. Indeed, recent meta-analyses of randomized controlled trials using physical activity interventions reveal notable protective effects for dementia risk [9, 10].

Several nonhuman species have been used as animal models for the cognitive impairments associated with Alzheimer's disease [11]. Similar to the human studies, there is preliminary evidence from work in rodents [12–14] and primates [15] that exercise enhances cognitive function and leads to neurogenesis, potentially protecting against the development of dementia. However, current model systems have limited translational potential due to reliance on genetically homogenous populations studied in artificial environments. To date, most comparative studies have been conducted using transgenic mouse models that attempt to mimic specific aspects of Alzheimer's disease neuropathology, including the pathological deposition of amyloid- β ($A\beta$) plaques and neurofibrillary tangles with hyperphosphorylated tau [16]. However, these models have typically focused on the least prevalent form in humans [17]. No mouse model exhibits the full progression of Alzheimer's disease, and the supraphysiological overexpression of amyloid precursor protein transgenes may alter brain development in ways that limit translational potential [18]. In addition, studies with laboratory mice have limited ability to model the complex gene \times environment interactions believed to underlie the heterogeneity observed in the development and progression of Alzheimer's disease [19].

G. E. Alexander
Arizona Alzheimer's Consortium, Phoenix, AZ, USA

G. E. Alexander
Department of Psychiatry, University of Arizona, Tucson, AZ, USA

G. E. Alexander
Neuroscience Graduate Interdisciplinary Program,
University of Arizona, Tucson, AZ, USA

G. E. Alexander
Physiological Sciences Graduate Interdisciplinary
Program, University of Arizona, Tucson, AZ, USA

E. L. MacLean
Cognitive Science Program, University of Arizona,
Tucson, AZ, USA

E. L. MacLean
College of Veterinary Medicine, University of Arizona,
Tucson, AZ, USA

Companion dogs have been proposed as a model for aging research with high translational potential [20–22]. Unlike laboratory populations, companion dogs are genetically heterogeneous, and share many important features with humans, including the same living environments, disease risks and burdens, patterns of actuarial aging, and access to a sophisticated health care system [23]. Dogs have also been suggested as a valuable natural complementary model for the age-related dementia of Alzheimer's disease. With advanced age, many dogs spontaneously develop a range of cognitive and behavioral impairments that resemble those associated with brain aging and Alzheimer's dementia. Dozens of studies have shown that signs of age-related neurodegeneration in dogs are often accompanied by cognitive dysfunction in learning and memory analogous to impairments often seen in human aging and Alzheimer's disease [24–28]. Although the full complement of Alzheimer's disease neuropathology has yet to be consistently observed in any naturally occurring nonhuman animal model, Alzheimer-like pathology, e.g., A β 1–42, increases with age in companion dogs [29, 30] and has been described in the context of diffuse plaque deposition that has been related to cognitive decrements in older dogs [31]. There is also preliminary evidence for tauopathy, another feature of Alzheimer-like pathology, in the brains of dogs diagnosed with canine cognitive dysfunction [32].

In addition, similar to humans, physical activity as part of enriched environment and diet programs in dogs has been associated with reductions in A β Alzheimer-like pathology and improved cognitive performance [11]. Despite the strong potential for dog models of Alzheimer's disease, most studies to date have used small laboratory samples that do not capitalize on the many potential benefits of a companion dog model (e.g., large heterogeneous populations living in the same environments as humans).

Previous exploratory work has looked broadly for associations between a wide range of characteristics and canine cognitive dysfunction, finding that age and a single rating of physical activity were associated with canine cognitive dysfunction [33]. Building upon these findings, in the current observational study, we focused our investigation on the relationship between physical activity and age-related

impairments in cognitive function in companion dogs, using questionnaire data generated by the Dog Aging Project. Specifically, owners were asked to report the dog's lifestyle (not active to active) as well as the typical duration and intensity of their dog's physical activity. This dataset was analyzed alongside the owners' responses to a validated instrument [34] assessing behaviors indicative of cognitive dysfunction and dementia (i.e., challenges in navigation, searching, and recognition; changes in social activity). We hypothesized that higher levels of physical activity would be associated with lower (i.e., better) scores on a cognitive dysfunction rating instrument and decreased risk of dementia, and that this association would be robust when controlling for age, comorbidities (e.g., motor impairments, exercise intolerance), and lifestyle factors that potentially affect physical activity (e.g., joint supplements). Additionally, given that we know little about potential risk factors and protective effects for canine dementia, we also examined associations between several lifestyle factors (i.e., use of neuroprotective supplements and engagement in formal dog training activities) and categories of health conditions (i.e., neurologic conditions, sensory deficits, periodontal disease, and liver failure) with dementia outcomes.

Methods

Subjects

All dogs were members of the Dog Aging Project (DAP), a nationwide research study of companion dogs that aims to better understand the biological and environmental factors that impact health span and lifespan [20, 22]. While the DAP is an ongoing longitudinal study, the current study used a cross-sectional approach incorporating data from the 2021 curated data release from this project. Owners completed the requested online surveys between December 26, 2019, and December 31, 2020 [35]. Study data were collected and managed using REDCap electronic data capture tools hosted through the DAP [36, 37]. These data are publicly available and housed on the Terra platform at the Broad Institute of MIT and Harvard.

Instruments

Upon enrollment in the DAP, owners completed the Health and Life Experience Survey (HLES). In addition to collecting dog and owner demographics, this detailed questionnaire also asked owners to report on their dog's physical activity, environment, behavior, diet, medications and preventatives, and health status. For the current study, we were mainly interested in the data reflecting physical activity and health status.

After completing HLES, all participants were asked to participate in a second survey: the Canine Social and Learned Behavior Survey (CSLB). The intent of this survey was to measure owner report of cognitive function. The CSLB, renamed by the DAP, is based on the Canine Cognitive Dysfunction Rating Scale (CCDR) [34], with minor wording modifications to select items. The CCDR was presented to participants as the Canine Social and Learned Behavior Survey to avoid the negative connotations of the phrase "cognitive dysfunction." This instrument asks owners to indicate the frequency with which their dogs exhibit behaviors indicative of cognitive dysfunction and dementia (i.e., difficulty in navigation, searching, and recognition; disengagement from social activity). Based on owner responses, dogs receive a score that ranges from 16 to 80, where higher scores are indicative of worse cognitive function. This instrument was previously validated in a sample of dogs 8 years and older as a way of distinguishing dogs with CCD from those without [34]. In the current manuscript, we also explored its utility as a continuous measure.

During the study period, we received HLES responses from 27,541 unique DAP participants, of which 20,096 went on to also complete a CSLB.

Ethical note

The University of Washington IRB deemed that recruitment of dog owners for the DAP and the administration and content of the DAP HLES are human subjects research that qualifies for Category 2 exempt status (IRB ID no. 5988, effective 10/30/2018). No interactions between researchers and privately owned dogs occurred; therefore, IACUC oversight was not required.

Inclusion/exclusion criteria

Given that cognitive decline is not typically observed in dogs until at least 6 years of age [27, 38, 39], we specified age of inclusion as $6 \leq \text{age} < 18$ years at the time of CSLB completion.

After applying this exclusion criterion, the final sample consisted of 11,574 dogs whose owners completed both the HLES and CSLB surveys. CSLB was always completed at least 1 week after completion of HLES. Most participants in the final sample (87.8%) completed CSLB within 3 months of completing HLES and always within 1 year (range: 7 to 352 days, mean: 47.14 days).

Outcome variable

Our outcome of interest was the owner-reported symptoms of cognitive dysfunction for each dog, which we measured via three scores derived from CSLB responses. We first performed principal components analysis (PCA) on the 13 response items (see SI 1, Appendix A for survey questions). Parallel analysis recommended retaining two principal components. We used an oblimin rotation to allow correlation between the two components (see Table S1 in SI 1 for loadings). The first component, which we called "change," was loaded highly by questions regarding reported changes in cognitive dysfunction symptoms over the prior 6 months. The second component, which we called "severity," was loaded highly by items measuring reported current symptom severity. Finally, we analyzed canine cognitive dysfunction (CCD) status as a binary exposure, wherein dogs who scored 50 or above were deemed to be above the diagnostic clinical threshold for CCD, and dogs below this score were not [34].

Predictor variables

Our main predictor of interest was physical activity. To calculate this variable for each dog, we performed PCA on three HLES-reported variables regarding activity over the past year: lifestyle activity level (reported as not active, moderately active, or very active), average activity intensity level (reported as low: walking; medium: jogging; or vigorous: sprinting, such as playing fetch or frisbee), and average daily time spent physically active (reported in hours

and minutes). Parallel analysis recommended retaining one principal component from these measures (see Table S2 in SI 1 for loadings). This principal component explained 56% of the variance and was loaded positively by all three questions regarding physical activity. We used the scores from this component as our measure of physical activity (PA score). Initial exploratory analyses suggested substantial and linear declines in physical activity with age (Fig. S1 in SI 1).

We used information reported in HLES about diverse medical conditions with potential to influence cognitive function or physical activity level as covariates. Specifically, based on past literature, we expected the following health-related factors to be associated with risk of cognitive impairment in dogs: neurologic conditions, such as epilepsy [40–42], sensory deficits in the visual and auditory domains [43–45], periodontal disease [46–48], and liver failure [49, 50].

We also created covariates for orthopedic conditions and exercise intolerance, which we expected to be negatively associated with physical activity levels. In the exercise intolerance category, we accounted for cardiac and respiratory conditions that negatively affect a dog's ability to exercise—either by rendering the dogs unable to exert themselves physically or because the prevailing veterinary advice for the diagnosis is restricted activity.

Lastly, to control for other factors potentially influencing general health, we created variables for whether dogs had been diagnosed with certain systemic disorders, including cancer and those affecting the kidneys and the endocrine system.

For each of the health condition categories described above, all participants were assigned a binary score (affected/unaffected). Dogs were considered “affected” if their owner reported them to have one or more relevant conditions within a given category. We only included chronic conditions that were likely to affect the relevant systems, and thus excluded temporary conditions that, given standard recommended medical care, would only temporarily affect the relevant systems. For example, in the orthopedic category, we scored hip dysplasia as an “affected” condition, as it is a long-term issue that affects mobility, whereas fractured bones were not included because the most likely prognosis

is complete recovery and therefore the impact on physical activity is temporary. For cataracts and ligament ruptures, we only included dogs as affected (in the sensory impairment and orthopedic categories, respectively) if the diagnosis was *not* followed by surgery. Our curated list of health conditions included in each covariate category can be found in SI 2, and the full list of health conditions that owners were asked about is presented in SI 3.

Additionally, we created covariates for lifestyle factors that preliminary evidence suggests might affect physical activity and/or cognition. If dogs received glucosamine and/or other joint supplements daily, they were considered “affected” in the joint supplement category [51]. If dogs received omega 3, vitamins, probiotics, antioxidants, taurine, carnitine, and/or coenzyme Q10 daily, they were considered “affected” in the neuroprotective supplement category [26, 52–55]. We also created a variable accounting for whether a dog had a history of training [56], given intriguing preliminary evidence that this sort of enrichment is linked to delay in cognitive decline [45, 56, 57]. Training history was determined according to what the owner reported as the dog's primary or secondary activity (e.g., service dogs, agility dogs, and dogs trained for field trials vs. pets/companion, see SI 1, Appendix B for full details). Finally, we included a variable accounting for the age of the owner; in preliminary analyses of the current dataset as well as other analyses of the Dog Aging Project data [58, 59], owner age was correlated with dog activity levels. It is possible that owner age affects the actual activity of the dog (e.g., older owners might have more time to spend with their dog in active pursuits), as well as the way that the owner perceives and reports the activity of their dog (a confounder).

A summary of the demographic variables, incidence of health conditions, physical activity levels, training history, and dietary supplement use within our sample is reported in Table 1, broken down by participants who met the diagnostic score for CCD ($n=287$; 2.48% of sample) and those who did not ($n=11,287$).

Statistical methods

All statistical analyses were carried out in R v.4.0.3 [60].

Table 1 Summary statistics of our sample. For health conditions and training history, values reflect the proportion of dogs affected in each group. For physical activity, values represent standardized principal component scores

Variables	Canine cognitive dysfunction case (score ≥ 50)			Canine cognitive dysfunction control (score < 50)		
	<i>N</i>	Mean	SD	<i>N</i>	Mean	SD
Age	287	14.15	2.32	11,287	10.10	2.61
Sex	287			11,287		
Female intact	3	1.05%		85	0.75%	
Female spayed	133	46.34%		5668	50.22%	
Male intact	7	2.44%		304	2.69%	
Male neutered	144	50.17%		5230	46.34%	
Dog weight (lbs)	287	33.56	24.73	11,287	48.9	28.57
Physical activity	287	-0.79	0.83	11,287	0.02	1
Training history	287	0.10	0.30	11,287	0.18	0.39
Neurological	287	0.18	0.38	11,287	0.07	0.25
Periodontal	287	0.37	0.48	11,287	0.24	0.43
Exercise Intolerance	287	0.13	0.34	11,287	0.07	0.25
Orthopedic	287	0.41	0.49	11,287	0.21	0.41
Sensory Impairment	287	0.63	0.48	11,287	0.13	0.34
Neuroprotective Supplement	287	0.37	0.48	11,287	0.37	0.48
Joint supplement	287	0.45	0.50	11,287	0.40	0.49
Endocrine	287	0.13	0.34	11,287	0.05	0.22
Kidney	287	0.09	0.28	11,287	0.01	0.12
Cancer	287	0.17	0.38	11,287	0.09	0.29
Liver	287	0.02	0.14	11,287	0.01	0.08

We fit three tiers of models for each of our outcome variables. In our first tier of analysis, we built a base model that included only key predictor variables (physical activity and age) and a minimal set of covariates. The effect of age was modeled using a second-order polynomial term because preliminary exploratory analyses revealed a non-linear relationship between age and the cognitive outcomes (see Fig. S2 in SI 1). The other covariates included in our base models included dog sex (female, intact; female, spayed; male, intact; male, neutered), dog size (lbs), and owner age (18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75 and older). For models using the categorical measure of dementia status as the outcome, the owner age variable was collapsed to two levels (18–54, 55 and older) and dog sex was collapsed to two levels (male, female) to avoid small cell sizes.

In our second tier of analysis, we built a model that included all the variables from our base model as well as hypothesis-driven confounders and risk or

protective factors. The additional variables for these models included whether a given dog exhibited sensory impairments (e.g., visual and/or auditory), motor impairments (e.g., orthopedic challenges), exercise intolerance (e.g., cardiac and/or respiratory challenges), neurological conditions other than dementia (i.e., dogs with a reported diagnosis of dementia or senility—and no other neurological conditions—were considered “unaffected” in this category), periodontal disease, and liver disease, as well as whether they were currently receiving joint and/or neuroprotective supplements, and whether they had a history of training. For models using the categorical measure of dementia as the outcome, liver disease was removed as a covariate due to small cell sizes when stratifying on this covariate.

Finally, in the third tier of analysis, we added the remaining, non-hypothesis-driven covariates, for health condition categories including endocrine disease, kidney disease, and cancer.

We applied our three-tier modeling approach to the three different outcome variables, using linear regressions for symptom severity and recent symptom change, and a logistic regression for CCD status. Continuous outcomes (severity and change) were subjected to an inverse rank normal transformation to better meet the assumptions of linear modeling, and then standardized to have a mean of 0 and standard deviation of 1, to facilitate interpretation. We fit a total of nine statistical models (three for each dependent measure). To identify the best model for each outcome, we compared the Akaike information criterion scores across models.

We also performed some sensitivity analyses. To determine if any observed associations would still hold in a cognitively healthy population, we re-ran our original analyses but removed all dogs above the CCD threshold ($n=11,287$, Tables S3 and S4 in SI 1). Given that over half of our sample was comprised of mixed breed dogs ($n=6027$ (52%)), a highly heterogeneous group, we did not control for breed in our main analyses. Thus, in a follow-up set of sensitivity analyses, we first repeated all models but eliminated all purebred dogs from the sample ($n=6027$, Tables S5–S7 in SI 1). Additionally, we then repeated all models but only included purebred dogs—using breeds with at least 10 dogs in the dataset ($n=5167$ dogs from 92 breeds; Table S8 in SI 1), and, for the CCD model, at least one member of the breed above the CCD threshold ($n=3945$ dogs from 53 breeds; Table S9 in SI 1)—and added breed as a covariate (Tables S5–S7 in SI 1). Finally, based on the possibility that CSLB scores below 20 may be implausible, we re-ran the models from our main analyses, excluding the subset of dogs with a score of 19 and lower ($n=11,368$; see Tables S10–S12 in SI 1 for details).

Results

For all outcomes, results from each of the three tiers of analysis displayed the same pattern but the fully adjusted model fit the best in all cases, as determined by the Akaike information criterion (Tables 2, 3, 4). Therefore, the results reported below are derived from the models including all candidate covariates.

As expected, all three cognitive outcomes were negatively associated with age, with effect of age increasing at older ages (Fig. 1). In all models, there

was also a significant relationship between physical activity and cognitive outcomes (Fig. 2).

In the severity model, we found a significant negative association between physical activity and severity of cognitive symptoms, whereby high levels of activity were linked to lower (i.e., better) scores on the CSLB (Fig. 2; Table 2). We also identified associations between two other hypothesized protective factors (training history and neuroprotective supplements), in which both a history of training and daily consumption of neuroprotective supplements were associated with better cognitive outcomes. For the final hypothesized protective factor (joint supplements), the beta coefficient was negative but not statistically significant. We also observed that poor health in certain domains was a risk factor for symptom severity. For our medical covariates, beta coefficients were positive and statistically significant for six categories of conditions (sensory impairment, endocrine, orthopedic, neurological, cancer, and periodontal) and positive but not statistically significant for the final three categories of conditions (kidney, liver, and exercise intolerance; Fig. 2; Table 2). Results were similar in the analysis that excluded dogs above the CCD threshold (Table S3 in SI 1), suggesting that these relationships hold below the clinical cutoff for a diagnosis of dementia. Results were also similar in secondary analyses including only mixed breed dogs or only purebred dogs from the most common breeds (see Table S5 in SI 1). Across all three models, the negative association between symptom severity and our main exposure of interest (physical activity) remained significant, as did the negative associations with training history and neuroprotective supplements and the positive associations with two categories of medical conditions (sensory impairment and orthopedic). Finally, removing dogs with reported CSLB scores less than 20 did not change our findings (Table S10 in SI 1).

In the symptom change model, we again found a significant negative relationship between physical activity and reported change in cognitive symptoms as recalled by owners over the prior 6-month period, whereby higher levels of activity were linked to less owner-reported cognitive decline across the preceding 6 months (Fig. 2; Table 3). We also identified a negative association with one of our other hypothesized protective factors (training history), in which dogs with an extensive training history exhibited less

Table 2 Model comparisons between the three tiers of models predicting symptom severity, reporting the beta coefficients and the 95% confidence interval based on robust standard errors in parentheses. Dog age was included in all models as a second-order polynomial term, and age effects are shown separately in Fig. 1

Symptom severity						
Parameter	Minimally adjusted		Moderately adjusted		Fully adjusted	
	Beta (95% CI) ¹	<i>p</i> value	Beta (95% CI) ¹	<i>p</i> value	Beta (95% CI) ¹	<i>p</i> value
Physical activity	−0.116 (−0.134 to −0.098)	<0.001	−0.096 (−0.114 to −0.079)	<0.001	−0.095 (−0.113 to −0.077)	<0.001
Dog weight (lbs)	0.000 (−0.001 to 0.000)	0.123	0.000 (−0.001 to 0.001)	0.720	0.000 (−0.001 to 0.001)	0.941
Sex						
Female intact	—		—		—	
Female spayed	0.238 (0.056 to 0.419)	0.010	0.198 (0.020 to 0.376)	0.029	0.195 (0.018 to 0.373)	0.031
Male intact	0.208 (0.004 to 0.411)	0.046	0.171 (−0.029 to 0.372)	0.093	0.170 (−0.030 to 0.370)	0.096
Male neutered	0.290 (0.108 to 0.471)	0.002	0.244 (0.066 to 0.422)	0.007	0.243 (0.066 to 0.420)	0.007
Owner age						
18–24	—		—		—	
25–34	−0.348 (−0.567 to −0.129)	0.002	−0.336 (−0.545 to −0.127)	0.002	−0.334 (−0.542 to −0.125)	0.002
35–44	−0.578 (−0.794 to −0.362)	<0.001	−0.556 (−0.762 to −0.350)	<0.001	−0.554 (−0.759 to −0.348)	<0.001
45–54	−0.725 (−0.939 to −0.510)	<0.001	−0.710 (−0.915 to −0.505)	<0.001	−0.707 (−0.911 to −0.503)	<0.001
55–64	−0.876 (−1.09 to −0.664)	<0.001	−0.861 (−1.06 to −0.658)	<0.001	−0.856 (−1.06 to −0.654)	<0.001
65–74	−0.99 (−1.20 to −0.774)	<0.001	−0.97 (−1.18 to −0.772)	<0.001	−0.97 (−1.17 to −0.767)	<0.001
75 and older	−1.07 (−1.29 to −0.852)	<0.001	−1.05 (−1.26 to −0.844)	<0.001	−1.05 (−1.25 to −0.839)	<0.001
Sensory impairment			0.408 (0.351 to 0.464)	<0.001	0.405 (0.349 to 0.461)	<0.001
Orthopedic			0.087 (0.044 to 0.130)	<0.001	0.084 (0.041 to 0.127)	<0.001
Exercise intolerance			0.045 (−0.020 to 0.111)	0.177	0.043 (−0.023 to 0.108)	0.203
Neurological			0.076 (0.008 to 0.143)	0.028	0.073 (0.005 to 0.140)	0.035
Periodontal			0.063 (0.024 to 0.101)	0.002	0.060 (0.021 to 0.099)	0.003
Liver			0.041 (−0.182 to 0.264)	0.720	0.030 (−0.193 to 0.253)	0.790
Joint supplement			−0.032 (−0.074 to 0.009)	0.125	−0.031 (−0.073 to 0.010)	0.139
Neuroprotective supplement			−0.078 (−0.119 to −0.038)	<0.001	−0.082 (−0.123 to −0.042)	<0.001
Training history			−0.079 (−0.122 to −0.037)	<0.001	−0.080 (−0.122 to −0.037)	<0.001
Endocrine					0.085 (0.009 to 0.161)	0.029
Kidney					0.112 (−0.025 to 0.248)	0.109
Cancer					0.057 (0.001 to 0.113)	0.047
AIC	30,326		30,010		30,003	

¹CI, confidence interval

cognitive decline in the preceding 6 months. For the two other hypothesized protective factors (neuroprotective and joint supplements), the beta coefficients

were near zero and not statistically significant. We also found evidence that poor health in certain domains was a risk factor for symptoms worsening

Table 3 Model comparisons between the three tiers of models predicting cognitive decline in previous six months, reporting the beta coefficients and the 95% confidence interval based on robust standard errors in parentheses. Dog age was included in all models as a second-order polynomial term, and age effects are shown separately in Fig. 1

Symptom change; previous 6 months						
Parameter	Minimally adjusted		Moderately adjusted		Fully adjusted	
	Beta (95% CI) ¹	<i>p</i> value	Beta (95% CI) ¹	<i>p</i> value	Beta (95% CI) ¹	<i>p</i> value
Physical activity	−0.086 (−0.104 to −0.068)	<0.001	−0.070 (−0.089 to −0.052)	<0.001	−0.069 (−0.087 to −0.051)	<0.001
Dog weight (lbs)	0.001 (0.000 to 0.002)	<0.001	0.001 (0.000 to 0.002)	0.001	0.001 (0.000 to 0.002)	0.004
Sex						
Female intact	—		—		—	
Female spayed	0.114 (−0.089 to 0.318)	0.271	0.074 (−0.126 to 0.274)	0.469	0.072 (−0.127 to 0.272)	0.479
Male intact	0.044 (−0.184 to 0.272)	0.704	0.008 (−0.217 to 0.232)	0.947	0.008 (−0.215 to 0.232)	0.942
Male neutered	0.126 (−0.078 to 0.330)	0.225	0.082 (−0.118 to 0.283)	0.421	0.082 (−0.118 to 0.282)	0.421
Owner age						
18–24	—		—		—	
25–34	−0.034 (−0.358 to 0.290)	0.835	−0.037 (−0.357 to 0.283)	0.820	−0.033 (−0.353 to 0.286)	0.839
35–44	−0.067 (−0.389 to 0.255)	0.684	−0.063 (−0.382 to 0.255)	0.696	−0.060 (−0.378 to 0.258)	0.713
45–54	−0.038 (−0.359 to 0.283)	0.815	−0.038 (−0.355 to 0.279)	0.815	−0.033 (−0.349 to 0.284)	0.841
55–64	−0.019 (−0.339 to 0.301)	0.907	−0.018 (−0.334 to 0.298)	0.911	−0.010 (−0.326 to 0.305)	0.949
65–74	−0.081 (−0.401 to 0.239)	0.618	−0.086 (−0.402 to 0.230)	0.595	−0.077 (−0.393 to 0.238)	0.632
75 and older	−0.112 (−0.437 to 0.212)	0.498	−0.103 (−0.424 to 0.218)	0.528	−0.095 (−0.415 to 0.226)	0.562
Sensory impairment			0.233 (0.169 to 0.297)	<0.001	0.230 (0.166 to 0.294)	<0.001
Orthopedic			0.156 (0.108 to 0.204)	<0.001	0.153 (0.106 to 0.201)	<0.001
Exercise intolerance			0.056 (−0.019 to 0.132)	0.146	0.054 (−0.021 to 0.130)	0.161
Neurological			0.089 (0.013 to 0.165)	0.021	0.087 (0.011 to 0.163)	0.025
Periodontal			0.066 (0.023 to 0.108)	0.003	0.063 (0.020 to 0.106)	0.004
Liver			−0.012 (−0.289 to 0.265)	0.930	−0.023 (−0.298 to 0.253)	0.872
Joint supplement			0.015 (−0.029 to 0.059)	0.504	0.016 (−0.028 to 0.060)	0.477
Neuroprotective supplement			0.001 (−0.042 to 0.044)	0.972	−0.003 (−0.046 to 0.040)	0.888
Training history			−0.055 (−0.100 to −0.010)	0.016	−0.056 (−0.101 to −0.010)	0.016
Endocrine					0.033 (−0.056 to 0.122)	0.464
Kidney					0.089 (−0.091 to 0.268)	0.333
Cancer					0.106 (0.043 to 0.170)	0.001
AIC	31,513		31,365		31,356	

¹CI, confidence interval

over a 6-month period. For our medical covariates, beta coefficients were positive and statistically significant for five categories of medical conditions

(sensory impairment, orthopedic, neurological, cancer, and periodontal), and not statistically significant for four categories of conditions (kidney, endocrine,

Table 4 Model comparisons between the three tiers of models predicting CCD status, reporting the odds ratio and the 95% confidence interval in parentheses. Dog age was included in all

models as a second-order polynomial term, and age effects are shown separately in Fig. 1

Canine cognitive dysfunction (clinical cutoff)						
Parameter	Minimally adjusted		Moderately adjusted		Fully adjusted	
	OR (95% CI) ¹	<i>p</i> value	OR (95% CI) ¹	<i>p</i> value	OR (95% CI) ¹	<i>p</i> value
Physical activity	0.51 (0.43 to 0.60)	<0.001	0.53 (0.45 to 0.62)	<0.001	0.53 (0.45 to 0.63)	<0.001
Dog weight (lbs)	0.99 (0.99 to 1.00)	0.003	0.99 (0.99 to 1.00)	0.008	0.99 (0.99 to 1.00)	0.006
Dog sex						
Male	—		—		—	
Female	0.85 (0.66 to 1.09)	0.198	0.85 (0.65 to 1.09)	0.202	0.83 (0.64 to 1.07)	0.152
Owner age						
18–54	—		—		—	
55 and older	0.78 (0.61 to 1.01)	0.062	0.75 (0.58 to 0.97)	0.029	0.78 (0.60 to 1.02)	0.070
Sensory impairment			3.23 (2.45 to 4.28)	<0.001	3.20 (2.43 to 4.24)	<0.001
Orthopedic			1.22 (0.92 to 1.61)	0.160	1.22 (0.92 to 1.62)	0.162
Exercise intolerance			0.98 (0.66 to 1.43)	0.928	0.97 (0.65 to 1.42)	0.887
Neurological			1.31 (0.91 to 1.86)	0.137	1.29 (0.89 to 1.84)	0.162
Periodontal			0.80 (0.60 to 1.05)	0.105	0.78 (0.59 to 1.02)	0.076
Joint supplement			0.96 (0.70 to 1.32)	0.822	1.00 (0.72 to 1.37)	0.979
Neuroprotective supplement			1.02 (0.74 to 1.40)	0.898	0.97 (0.71 to 1.34)	0.872
Training history			0.75 (0.48 to 1.12)	0.174	0.72 (0.46 to 1.09)	0.133
Endocrine					1.46 (0.97 to 2.16)	0.062
Kidney					1.85 (1.09 to 3.04)	0.017
Cancer					1.15 (0.80 to 1.61)	0.437
AIC	1,977		1,911		1,908	

¹OR, odds ratio; CI, confidence interval




Fig. 1 The estimated association between age and symptom severity (PCA-derived score), symptom change in last 6 months (PCA-derived score), and probability of a CCD diag-

nosis, respectively (with 95% confidence intervals indicated in gray). Results are from our fully adjusted models and include both linear and quadratic terms for age




Fig. 2 The beta coefficients (for the severity and change models) and odds ratios (for the CCD diagnosis model) of physical activity, as well as the other lifestyle (joint supplement, neuroprotective supplement, training history) and medical (sensory impairment, kidney, endocrine, orthopedic, neurological, cancer, liver, exercise intolerance, periodontal) covariates from

the fully adjusted models. The red dotted line indicates the null expectation (i.e., 0 for the betas and 1 for the odds ratios). Significant findings are presented in black, while nonsignificant findings are presented in gray. The bars represent the 95% confidence intervals

exercise intolerance, and liver). Results were similar when performing our original analyses but removing all dogs above the CCD threshold (Table S4 in SI 1), suggesting that these relationships hold below the clinical cutoff for a diagnosis of dementia. Results were also similar in secondary analyses including only mixed breed dogs or only purebred dogs from the most common breeds (see Table S6 in SI 1): across all three models, the negative association between symptom change and physical activity remained significant, as did the positive associations with three categories of medical conditions (sensory impairment, orthopedic, and periodontal). Finally, removing dogs with reported CSLB scores less than 20 did not change our findings (Table S11 in SI 1).

In the CCD status model, we found that higher levels of physical activity were associated with lower odds of being over the diagnostic threshold for CCD (Fig. 2; Table 4). The adjusted odds ratio was 0.53 (95% CI: 0.45 to 0.63) and statistically significant for physical activity, but there were no significant

associations with the other hypothesized protective factors (training history, neuroprotective supplements, and joint supplements). We also found evidence that poor health in certain domains was associated with CCD, whereby individuals with CCD were also likely to have other owner-reported health issues. For our medical covariates, we observed OR > 1.0 and statistically significant for three categories of medical conditions (sensory impairment, kidney, and endocrine) with none of the other six categories of conditions (orthopedic, neurological, cancer, liver, exercise intolerance, and periodontal) reaching statistical significance. Results were similar in secondary analyses including only mixed breed dogs and dogs from the most common breeds (see Table S7 in SI 1 for full report): across all three models, the negative association between being over the diagnostic threshold for CCD and physical activity remained significant, as did the positive association with sensory impairment. Removing dogs with reported CSLB scores less than 20 did not change our findings (Table S12 in SI 1).

Discussion

We investigated the relationship between physical activity and cognitive health in a sample of over 10,000 companion dogs. By exploring this relationship in a large population living in an environment shared with humans, we aimed to gain insight regarding factors associated with healthy cognitive aging and to identify potential modifiable risk factors that may prevent cognitive dysfunction and dementia [61].

Across all models, we observed robust associations between physical activity and cognitive health. Physical activity was significantly negatively associated with three metrics of cognitive dysfunction: current symptom severity, extent of worsening over a 6-month interval, and whether a dog had reached a clinical threshold for CCD. These results held when controlling for basic demographic factors (weight, sex, and age of the dog, as well as age of the owner), hypothesis-driven protective and risk factors related to lifestyle (joint-enhancing supplements, neuroprotective supplements, and training history) and health (sensory impairments, exercise intolerance, orthopedic conditions, neurological conditions other than dementia, periodontal disease, liver conditions), and other general health conditions (endocrine conditions, kidney failure, and cancer). Interestingly, only 2.5% of subjects in the current study passed the clinical threshold for CCD, which is much lower than the proportion reported in previous research [34]. Although we cannot determine the cause of this difference, it is important to recognize factors that may influence variance in prevalence estimates across studies. First, our sample size was considerably larger than those used in initial studies of CCD. Second, our sample was comprised entirely of dogs in the USA, in contrast to the earlier work by Salvin et al. [34], which included dogs from 11 countries, but predominantly from Australia. Third, it is possible that participants in this study, and others, may not be fully representative of the broader population of companion dogs and their owners (e.g., due to demographic biases associated with self-selection into research studies). Therefore, obtaining unbiased estimates of CCD prevalence remains an important priority for future research.

Our sensitivity analyses indicated that the association between physical activity and cognitive function held even when dogs who met the CCD threshold were removed from the sample. Thus, even in

non-clinical cohorts, physical activity may be associated with cognitive benefits in older dogs, and/or declines in cognitive function may be associated with declines in owner-reported physical activity. This finding also indicates that principal component scores from the CSLB scale are sensitive to cognitive changes that could be precursors to the development of CCD. Although this possibility awaits empirical validation, our findings provide preliminary support for the utility of continuous scores derived from the CSLB.

In addition to the association between physical activity and cognition, our analyses revealed relationships between cognitive health and several other health and lifestyle variables. For example, one of the strongest observed associations was between CSLB scores indicating worse cognitive health and sensory impairment, in line with the findings of a similar questionnaire-based study of 1300 companion dogs [45]. While it may be that sensory impairment is a confounder (i.e., owners may mistakenly attribute a change in behavior to cognitive dysfunction when really it is the result of failing vision and/or audition), there is also evidence in the human literature that such impairments are potential risk factors for dementia [62–64]. Recent work in dogs suggests that loss of smell, hearing, and/or eyesight could similarly represent preclinical or early stages of CCD [65, 66].

We also found a positive association between taking daily neuroprotective supplements (e.g., fish oil) and cognitive symptom severity. This finding is consistent with some clinical studies in dogs [54, 55] and humans [67, 68], although other studies in the human literature have found no effect [69, 70]. A possible limitation of this finding is that owners who are motivated to provide potentially neuroprotective supplements may be biased in their evaluation of their pet's dementia symptoms. However, these supplements (e.g., fish oil) are also recommended by veterinarians for numerous other perceived benefits (e.g., heart health, coat shine, allergy relief, and pain management), so we do not know what expectations owners have regarding their potential effects on cognition.

Finally, we identified an association between two of our cognitive outcomes—symptom severity and cognitive change over the last 6 months—and training, whereby dogs who had a history of training were less likely to exhibit signs of cognitive decline. This finding is consistent with the idea that both physical

exercise *and* mental exercise can have a beneficial impact on the brain [1, 71, 72]. Furthermore, this measure accounted for previous activity (i.e., history of training versus current training regimen) and so, given the timeline, cannot be readily explained by reverse causality. While the literature in humans [73] and laboratory animals [74], including beagles [57, 75], supports the idea that enrichment can lead to better cognitive functioning in old age, only two other studies have demonstrated this relationship in companion dogs [45, 76], and a third study found no effect of lifelong training on behavioral and cognitive change [77]. Nonetheless, this relationship has interesting potential parallels to associations between cognitive training and educational attainment in the context of dementia and Alzheimer’s disease risk in humans [78].

Our study has several notable limitations. First, despite the large sample size and wide range of covariates accounted for, we cannot rule out unmeasured confounding. Second, all data were owner-reported and thus subject to potential pitfalls associated with self-report. Despite this limitation, the survey used in our analyses is known to have excellent diagnostic accuracy and test–retest reliability [34]. Third, we categorized dogs as either “affected” or “not affected” on each health covariate based on owner-reported diagnoses when filling out the HLES survey. However, HLES does not capture information about a condition’s severity. While all dogs were included in each category if they had a relevant diagnosis, in reality that condition might not have had a measurable impact. For example, we included all dogs with heart disease in our “exercise intolerance” category; in moderate to severe cases, this condition will inevitably impact a dog’s ability to exercise (and likely lead to a veterinary recommendation of exercise restriction). However, in mild cases, this condition may have minimal impact on a dog’s ability to exercise.

The most important limitation of our study is that we cannot determine causality given the observational, cross-sectional nature of the design. Given existing knowledge about the relationships between physical activity and cognitive function, it is plausible that higher rates of physical activity play a causal role in reducing risk of later-life cognitive impairment in dogs. However, the observed association between physical activity and cognitive outcomes could also

indicate that as dogs decline cognitively, it causes them to become less active. Finally, there is a third possibility of unmeasured confounding, whereby neither physical activity nor cognitive decline has causal effects on one another. The fact that our sensitivity analyses revealed an association between CSLB scores and physical activity even in clinically “normal” and/or preclinical dogs suggests that the first explanation is more likely; however, future research incorporating additional study designs, including interventions and the analysis of longitudinal data, will be critical for causal inferences in this domain. Also, our measures of physical activity reflect relatively recent patterns of physical activity and it is unknown whether these measures reflect a dog’s previous activity periods prior to enrollment, so this will be an important aim for future longitudinal analyses with this dataset.

In conclusion, our findings indicate that signs of cognitive decline in dogs, and the likelihood of developing CCD, increase with age, but that after adjusting for age, these outcomes are negatively associated with physical activity. These results are consistent with the hypothesis that physical activity may partially mitigate the risks of age-related cognitive impairment, although they are also consistent with the hypothesis that cognitively impaired dogs exercise less, or that unidentified confounding variables influence changes in both physical activity and cognitive function. We also identified several categories of medical conditions that were associated with cognitive dysfunction: sensory deficits showed the strongest associations, and there was also some evidence to suggest associations with endocrine disorders, neurological conditions, orthopedic impairments, periodontal disease, cancer, and kidney disorders. Across a subset of our outcome measures, training history and neuroprotective supplements were associated with reduced cognitive impairment. However, in support of our key hypothesis, physical activity was the only lifestyle factor that was robustly associated with reduced risk of cognitive dysfunction across all three of our outcome measures. These findings establish the value of companion dogs as a model for relationships between physical activity and cognitive aging, and lay a foundation for future longitudinal studies, including randomized controlled trials, with this valuable population.

Acknowledgements The Dog Aging Project thanks study participants, their dogs, and community veterinarians for their important contributions.

Dog Aging Project consortium authors Joshua M. Akey¹, Brooke Benton², Elhanan Borenstein^{3,4,5}, Marta G. Castelano^{6,7}, Amanda E. Coleman⁸, Kate E. Creevy⁹, Kyle Crowder^{10,11}, Matthew D. Dunbar¹¹, Virginia R. Fajt¹², Annette L. Fitzpatrick^{13,14,15}, Unity Jeffrey¹⁶, Erica C. Jonlin^{2,17}, Matt Kaeberlein², Elinor K. Karlsson^{18,19}, Kathleen F. Kerr²⁰, Jonathan M. Levine⁹, Jing Ma²¹, Robyn L. McClelland²⁰, Audrey Ruple²², Stephen M. Schwartz^{14,23}, Sandi Shrager²⁴, Noah Snyder-Mackler^{25,26,27}, M. Katherine Tolbert⁹, Silvan R. Urfer², Benjamin S. Wilfond.^{28,29}

¹Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.

²Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.

³Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

⁴Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel.

⁵Santa Fe Institute, Santa Fe, NM, USA.

⁶Cornell Veterinary Biobank, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.

⁷Department of Clinical Sciences, College of Veterinary Medicine Cornell University, Ithaca, NY, USA

⁸Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.

⁹Department of Small Animal Clinical Sciences, Texas A&M University College of Veterinary Medicine & Biomedical Sciences, College Station, TX, USA.

¹⁰Department of Sociology, University of Washington, Seattle, WA, USA.

¹¹Center for Studies in Demography and Ecology, University of Washington, Seattle, WA, USA.

¹²Department of Veterinary Physiology and Pharmacology, Texas A&M University College of Veterinary Medicine & Biomedical Sciences, College Station, TX, USA.

¹³Department of Family Medicine, University of Washington, Seattle, WA, USA.

¹⁴Department of Epidemiology, University of Washington, Seattle, WA, USA.

¹⁵Department of Global Health, University of Washington, Seattle, WA, USA.

¹⁶Department of Veterinary Pathobiology, Texas A&M University College of Veterinary Medicine & Biomedical Sciences, College Station, TX, USA.

¹⁷Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.

¹⁸Bioinformatics and Integrative Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.

¹⁹Broad Institute of MIT and Harvard, Cambridge, MA, USA.

²⁰Department of Biostatistics, University of Washington, Seattle, WA, USA.

²¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

²²Department of Population Health Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA.

²³Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

²⁴Department of Biostatistics, Collaborative Health Studies Coordinating Center, University of Washington, Seattle, WA, USA.

²⁵School of Life Sciences, Arizona State University, Tempe, AZ, USA.

²⁶Center for Evolution and Medicine, Arizona State University, Tempe, AZ, USA.

²⁷School for Human Evolution and Social Change, Arizona State University, Tempe, AZ, USA.

²⁸Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, Seattle, WA, USA.

²⁹Department of Pediatrics, Division of Bioethics and Palliative Care, University of Washington School of Medicine, Seattle, WA, USA.

Author contribution All authors contributed to writing—review and editing. E.B.: conceptualization, methodology, formal analysis, data curation, writing—original draft, and supervision. D.R.: conceptualization and methodology. K.F.: data curation. D.P.: conceptualization, project administration, and funding acquisition. G.A.: conceptualization and methodology. E.M.: conceptualization, methodology, formal analysis, writing—original draft, visualization, and supervision. DAP consortium: resources. G.A. and E.M. both contributed as senior authors.

Funding The Dog Aging Project is supported by U19AG057377 and R24AG073137 from the National Institute on Aging, a part of the National Institutes of Health, and by additional grants and private donations. The authors would also like to acknowledge support by the National Institute on Aging (P30AG019610, P30AG072980, R56AG067200, R01AG064587, R01AG072445, R01AG057330), the state of Arizona and Arizona Department of Health Services, and the Evelyn F. McKnight Brain Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data availability These data are housed on the Terra platform at the Broad Institute of MIT and Harvard.

Code availability This study did not use custom code or mathematical algorithms.

Declarations

Conflict of interest The authors declare no competing interests.

References

1. Raichlen DA, Alexander GE. Adaptive capacity: an evolutionary neuroscience model linking exercise, cognition, and brain health. *Trends Neurosci.* 2017;40(7):408–21.
2. Yu J-T, Xu W, Tan C-C, Andrieu S, Suckling J, Evangelou E, . . . Feng L. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. *J Neurol Neurosurg Psychiatry.* 2020;91(11):1201–1209
3. Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. *Mayo Clin Proc.* 2011;86(9):876–84.
4. Santos-Lozano A, Pareja-Galeano H, Sanchis-Gomar F, Quindós-Rubial M, Fiuzza-Luces C, Cristi-Montero C, . . . Lucia A. Physical activity and Alzheimer disease: a protective association. Paper presented at the Mayo Clinic Proceedings. 2016
5. Lautenschlager NT, Cox KL, Flicker L, Foster JK, Van Bockxmeer FM, Xiao J, . . . Almeida OP. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. *Jama.* 2008;300(9):1027–1037
6. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, . . . White SM. Exercise training increases size of hippocampus and improves memory. *Proc National Acad Sci.* 2011;108(7):3017–3022
7. Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, Macchi C. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. *J Intern Med.* 2011;269(1):107–17.
8. Casaletto K, Ramos-Miguel A, VandeBunte A, Memel M, Buchman A, Bennett D, Honer W. Late-life physical activity relates to brain tissue synaptic integrity markers in older adults. *Alzheimer's & Dementia.* 2021;1–13. <https://doi.org/10.1002/alz.12530>.
9. Beckett MW, Arden CI, Rotondi MA. A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer's disease in older adults. *BMC Geriatr.* 2015;15(1):1–7.
10. Xu W, Wang HF, Wan Y, Tan C-C, Yu J-T, Tan L. Leisure time physical activity and dementia risk: a dose-response meta-analysis of prospective studies. *BMJ Open.* 2017;7(10):e014706.
11. Cotman CW, Berchtold NC. Physical activity and the maintenance of cognition: learning from animal models. *Alzheimers Dement.* 2007;3(2):S30–7.
12. Berchtold NC, Castello N, Cotman CW. Exercise and time-dependent benefits to learning and memory. *Neuroscience.* 2010;167(3):588–97.
13. Jahangiri Z, Gholamnezhad Z, Hosseini M. Neuroprotective effects of exercise in rodent models of memory deficit and Alzheimer's. *Metab Brain Dis.* 2019;34(1):21–37.
14. Van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. *J Neurosci.* 2005;25(38):8680–5.
15. Rhyu I, Bytheway J, Kohler S, Lange H, Lee K, Boklewski J, . . . Greenough W. Effects of aerobic exercise training on cognitive function and cortical vascularity in monkeys. *Neuroscience.* 2010;167(4):1239–1248
16. Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer's disease. *Mol Neurodegener.* 2017;12(1):1–22.
17. Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. *Front Genet.* 2014;5:88.
18. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. *Mount Sinai J Med.* 2010;77(1):69–81.
19. Chouliaras L, Sierksma A, Kenis G, Prickaerts J, Lemmens M, Brasnjevic I, . . . De Baets M. Gene-environment interaction research and transgenic mouse models of Alzheimer's disease. *Int J Alzheimer's Disease.* 2010. <https://doi.org/10.4061/2010/859101>
20. Creevy KE, Akey JM, Kaerberlein M, Promislow DE. An open science study of ageing in companion dogs. *Nature.* 2022;602(7895):51–7.
21. Fefer, G., Panek, W. K., Khan, M. Z., Singer, M., Westermeyer, H., Mowat, F. M., . . . Gruen, M. E.. Use of cognitive testing, questionnaires, and plasma biomarkers to quantify cognitive impairment in an aging pet dog population. *J Alzheimer's Disease (Preprint).* 2022; 1–12
22. Kaerberlein M, Creevy KE, Promislow DE. The dog aging project: translational geroscience in companion animals. *Mamm Genome.* 2016;27(7):279–88.
23. Hoffman JM, Creevy KE, Franks A, O'Neill DG, Promislow DE. The companion dog as a model for human aging and mortality. *Aging Cell.* 2018;17(3):e12737.
24. Head E. Neurobiology of the aging dog. *Age.* 2011;33(3):485–96.
25. Head E. A canine model of human aging and Alzheimer's disease. *Biochim Biophys Acta.* 2013;1832(9):1384–9.
26. Milgram NW, Head E, Zicker SC, Ikeda-Douglas C, Murphey H, Muggenberg BA, . . . Cotman CW. Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. *Exp Gerontol.* 2004;39(5):753–765
27. Packer RM, McGreevy PD, Salvin HE, Valenzuela MJ, Chaplin CM, Volk HA. Cognitive dysfunction in naturally occurring canine idiopathic epilepsy. *PLoS ONE.* 2018;13(2):e0192182.
28. Ruehl W, Bruyette D, DePaoli A, Cotman C, Head E, Milgram NW, Cummings B. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. *Prog Brain Res.* 1995;106:217–25.
29. Panek WK, Murdoch DM, Gruen ME, Mowat FM, Marek RD, Olby NJ. Plasma amyloid beta concentrations in aged and cognitively impaired pet dogs. *Mol Neurobiol.* 2021;58(2):483–9.
30. Urfer SR, Darvas M, Czeibert K, Sándor S, Promislow DE, Creevy K E., . . . Kaerberlein M. Canine

- cognitive dysfunction (CCD) scores correlate with amyloid beta 42 levels in dog brain tissue. *GeroScience*. 2021;43(5):2379–2386
31. Cotman CW, Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. *J Alzheimers Dis*. 2008;15(4):685–707.
 32. Abey A, Davies D, Goldsbury C, Buckland M, Valenzuela M, Duncan T. Distribution of tau hyperphosphorylation in canine dementia resembles early Alzheimer's disease and other tauopathies. *Brain Pathol*. 2021;31(1):144–62.
 33. Yarborough S, Fitzpatrick A, Schwartz SM, et al. Evaluation of cognitive function in the dog aging project: associations with baseline canine characteristics. *Sci Rep*. 2022;12:13316. <https://doi.org/10.1038/s41598-022-15837-9>.
 34. Salvin HE, McGreevy PD, Sachdev PS, Valenzuela MJ. The canine cognitive dysfunction rating scale (CCDR): a data-driven and ecologically relevant assessment tool. *Vet J*. 2011;188(3):331–6.
 35. Dog Aging Project. Dog Aging Project - 2020 Curated Data Release, version 1.1 [Data file and codebook]. 2021. <https://app.terra.bio/>. Accessed 17 Nov 2021: Terra at the Broad Institute of MIT and Harvard.
 36. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, . . . Kirby J. The REDCap consortium: building an international community of software platform partners. *J Biomed Informa*. 2019;95:103208
 37. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377–81.
 38. Harvey ND. How old is my dog? Identification of rational age groupings in pet dogs based upon normative age-linked processes. *Front Vet Sci*. 2021;8:643085. <https://doi.org/10.3389/fvets.2021.643085>.
 39. Studzinski CM, Christie L-A, Araujo JA, Burnham WM, Head E, Cotman CW, Milgram NW. Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. *Neurobiol Learn Mem*. 2006;86(2):197–204.
 40. Hobbs SL, Law TH, Volk HA, Younis C, Casey RA, Packer RM. Impact of canine epilepsy on judgement and attention biases. *Sci Rep*. 2020;10(1):1–11.
 41. Watson F, Packer RMA, Rusbridge C, Volk HA. Behavioural changes in dogs with idiopathic epilepsy. *Vet Record*. 2020;186(3):93–93.
 42. Winter J, Packer RMA, Volk HA. Preliminary assessment of cognitive impairments in canine idiopathic epilepsy. *Vet Record*. 2018;182(22):633–633.
 43. Fischer ME, Cruickshanks KJ, Schubert CR, Pinto AA, Carlsson CM, Klein BE, . . . Tweed TS. Age-related sensory impairments and risk of cognitive impairment. *J Am Geriatr Soc*. 2016;64(10):1981–1987
 44. Ford AH, Hankey GJ, Yeap BB, Golledge J, Flicker L, Almeida OP. Hearing loss and the risk of dementia in later life. *Maturitas*. 2018;112:1–11.
 45. Szabó D, Miklósi Á, Kubinyi E. Owner reported sensory impairments affect behavioural signs associated with cognitive decline in dogs. *Behav Proc*. 2018;157:354–60.
 46. Dewey CW, Rishniw M. Periodontal disease is associated with cognitive dysfunction in aging dogs: a blinded prospective comparison of visual periodontal and cognitive questionnaire scores. *Open Vet J*. 2021;11(2):210–6.
 47. Harding A, Gonder U, Robinson SJ, Crean S, Singhrao SK. Exploring the association between Alzheimer's disease, oral health, microbial endocrinology and nutrition. *Front Aging Neurosci*. 2017;9:398.
 48. Singhrao SK, Harding, A, Poole S, Kesavalu L, and Crean S. Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer's disease. *Mediat Inflamm*. 2015
 49. Butterworth RF. The concept of “the inflamed brain” in acute liver failure: mechanisms and new therapeutic opportunities. *Metab Brain Dis*. 2016;31(6):1283–7.
 50. Felipe V. Hepatic encephalopathy: effects of liver failure on brain function. *Nat Rev Neurosci*. 2013;14(12):851–8.
 51. McCarthy G, O'Donovan J, Jones B, McAllister H, Seed M, Mooney C. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. *Vet J*. 2007;174(1):54–61.
 52. Heath SE, Barabas S, Craze PG. Nutritional supplementation in cases of canine cognitive dysfunction—a clinical trial. *Appl Anim Behav Sci*. 2007;105(4):284–96.
 53. Mad'ari A, Farbakova J, Žilka N. Preventive and risk factors of canine dementia. In: Landsberg G, Mađari A, Žilka N, editors. *Canine and Feline Dementia*. Cham: Springer; 2017. https://doi.org/10.1007/978-3-319-53219-6_9.
 54. Pan Y, Kennedy AD, Jönsson TJ, Milgram NW. Cognitive enhancement in old dogs from dietary supplementation with a nutrient blend containing arginine, antioxidants, B vitamins and fish oil. *Br J Nutr*. 2018;119(3):349–58.
 55. Pan Y, Landsberg G, Mougeot I, Kelly S, Xu H, Bhatnagar S, . . . Milgram NW. Efficacy of a therapeutic diet on dogs with signs of cognitive dysfunction syndrome (CDS): a prospective double blinded placebo controlled clinical study. *Front Nutr*. 2018;5. <https://doi.org/10.3389/fnut.2018.00127>
 56. Bray EE, Zheng Z, Tolbert MK, McCoy BM, Kaeberlein M, Kerr KF. Once-daily feeding is associated with better health in companion dogs: results from the Dog Aging Project. *GeroScience*. 2022;44:1779–90. <https://doi.org/10.1007/s11357-022-00575-7>.
 57. Milgram NW, Siwak-Tapp CT, Araujo J, Head E. Neuroprotective effects of cognitive enrichment. *Ageing Res Rev*. 2006;5(3):354–69.
 58. Lee H, Collins D, Creevy KE, Promislow DE, Akey JM, Benton B, . . . Crowder K. Age and physical activity levels in companion dogs: results from the Dog Aging Project. *J Gerontol: Series A*. 2022
 59. McCoy BM, Brassington L, Jin K, Dolby GA, Shrager S, Collins D, . . . Consortium DAP. Social determinants of health and disease in companion dogs: a cohort study from the Dog Aging Project. *bioRxiv*. 2022
 60. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2016; Retrieved from <http://www.R-project.org>. Accessed 17 Nov 2021.
 61. Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Muñoz Sánchez JL, Anstey KJ, . . . Kivipelto M. Target

- risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. *Int J Geriatr Psychiatry*. 2015; 30(3):234–246
62. Hwang PH, Longstreth Jr W, Brenowitz WD, Thielke SM, Lopez OL, Francis CE, . . . Fitzpatrick AL. Dual sensory impairment in older adults and risk of dementia from the GEM Study. *Alzheimer's & Dementia*. 2020; 12(1):e12054
 63. Luo Y, He P, Guo C, Chen G, Li N, Zheng X. Association between sensory impairment and dementia in older adults: evidence from China. *J Am Geriatr Soc*. 2018;66(3):480–6.
 64. Maharani A, Dawes P, Nazroo J, Tampubolon G, Pendleton N. Associations between self-reported sensory impairment and risk of cognitive decline and impairment in the Health and Retirement Study cohort. *J Gerontol: Series B*. 2020;75(6):1230–42.
 65. Fefer G, Khan MZ, Panek WK, Case B, Gruen ME, Olby NJ. Relationship between hearing, cognitive function, and quality of life in aging companion dogs. *J Vet Intern Med*. 2022;1–11. <https://doi.org/10.1111/jvim.16510>.
 66. Ozawa M, Inoue M, Uchida K, Chambers JK, Takeuch Y, and Nakayama H. Physical signs of canine cognitive dysfunction. *J Vet Med Sci*. 2019; 19–0458
 67. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. *Nat Rev Neurol*. 2009;5(3):140–52.
 68. Nolan JM, Mulcahy R, Power R, Moran R, Howard AN. Nutritional intervention to prevent Alzheimer's disease: potential benefits of xanthophyll carotenoids and omega-3 fatty acids combined. *J Alzheimers Dis*. 2018;64(2):367–78.
 69. Danthiir V, Hosking DE, Nettelbeck T, Vincent AD, Wilson C, O'Callaghan N, . . . Wittert GA. An 18-mo randomized, double-blind, placebo-controlled trial of DHA-rich fish oil to prevent age-related cognitive decline in cognitively normal older adults. *The Am J Clin Nutrition*. 2018; 107(5):754–762
 70. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, OldeRikkert MG, . . . De Groot C. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. *Neurology*. 2008; 71(6):430–438
 71. Marx J. Preventing Alzheimer's: a lifelong commitment? Recent research suggests that keeping mentally and physically active when young and middle-aged can help stave off the brain degeneration of Alzheimer's. *Science*. 2005;309(5736):864–7.
 72. Raichlen DA, Bharadwaj PK, Nguyen LA, Franchetti MK, Zigman EK, Solorio AR, Alexander GE. Effects of simultaneous cognitive and aerobic exercise training on dual-task walking performance in healthy older adults: results from a pilot randomized controlled trial. *BMC Geriatr*. 2020;20(1):1–10.
 73. Kramer AF, Bherer L, Colcombe SJ, Dong W, Greenough WT. Environmental influences on cognitive and brain plasticity during aging. *J Gerontol A Biol Sci Med Sci*. 2004;59(9):M940–57.
 74. Birch AM, Kelly ÁM. Lifelong environmental enrichment in the absence of exercise protects the brain from age-related cognitive decline. *Neuropharmacology*. 2019;145:59–74.
 75. Milgram NW, Head E, Zicker S, Ikeda-Douglas C, Murphy H, Muggenburg B, . . . Cotman C. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. *Neurobiol Aging*. 2005; 26(1):77–90
 76. Chapagain D, Virányi Z, Wallis LJ, Huber L, Serra J, Range F. Aging of attentiveness in Border collies and other pet dog breeds: the protective benefits of lifelong training. *Front Aging Neurosci*. 2017;9:100.
 77. Chapagain D, Wallis LJ, Range F, Affenzeller N, Serra J, Virányi Z. Behavioural and cognitive changes in aged pet dogs: no effects of an enriched diet and lifelong training. *PLoS ONE*. 2020;15(9):e0238517.
 78. Xu W, Tan L, Wang H-F, Tan M-S, Tan L, Li J-Q, . . . Yu J-T. Education and risk of dementia: dose-response meta-analysis of prospective cohort studies. *Mol Neurobiol*. 2016; 53(5):3113–3123

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.